Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933

European Journal of Cancer

Volumn 38, Issue 8, 2002, Pages 1090-1099

  Van Zuylen, L ^a   Sparreboom, A ^a   Van der Gaast, A ^a   Nooter, K ^a   Eskens, F A L M ^a   Brouwer, E ^a   Bol, C J ^b   De Vries, R ^b   Palmer, P A ^b   Verweij, J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

MDR reversing agent; Multidrug resistance; Pharmacokinetics; Taxanes

Indexed keywords

DOCETAXEL; GLYCOPROTEIN P; LANIQUIDAR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DROWSINESS; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG MECHANISM; FECES; FEMALE; FEVER; HUMAN; IN VIVO STUDY; INFUSION; INTESTINE; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL; SOMNOLENCE; TIME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAZEPINES; BIOLOGICAL AVAILABILITY; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; QUINOLINES; TAXOIDS;

EID: 0036246308     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00035-7     Document Type: Article

References (25)

1. P-glycoprotein in adult solid tumors. Expression and prognostic significance
2. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
3. Reversal of multidrug resistance
4. Clinical trials of agents that reverse multidrug resistance
5. Are the major effects of P-glycoprotein modulators due to altered pharmacokinetics of anticancer drugs?
6. Development of multidrug-resistance convertors: Sense or nonsense?
7. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel
8. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans
9. A clinical pharmacodynamic (Pd) and pharmacokinetic (Pk) phase I study of I.V. R101933, an inhibitor of MDR1 P-glycoprotein (Pgp) given alone and in combination with Taxol in patients with solid tumors
10. Taxol metabolism and disposition in cancer patients
11. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography
12. Docetaxel (Taxotere): An overview of first line monotherapy
13. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
14. Functional imaging of multi-drug resistant P-glycoprotein with an organtechnetium complex
15. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein
16. Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m Sestamibi
17. Characterization of multidrug resistance P-glycoprotein transport function with an organotechnetium cation
18. Functional scintigraphy with technetium-99m MIBI does not correlate with histologic response to induction chemotherapy or measures of P-glycoprotein expression in high grade osteosarcoma
19. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918
20. Efflux of rhodamine from CD56+ cells as a surrogate marker for reversal of P-glycoprotein-mediated drug efflux by PSC 833
21. Reversal of P-glycoprotein is greatly reduced by the presence of plasma but can be monitored by an ex vivo clinical essay
22. Adequate tumour quinidine levels for multidrug resistance modulation can be achieved in vivo
23. Decreased potency of MDR-modulators under serum conditions determined by a functional assay
24. Serum can inhibit reversal of multidrug resistance by chemosensitizers
25. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal